Evolving Practice Patterns for Multiple Myeloma
EP. 1: Overview of Newly Diagnosed Multiple Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.
EP. 2: Standard Induction for Newly Diagnosed Symptomatic Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.
EP. 3: High-Risk Multiple Myeloma: Selecting Initial Therapy
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.
EP. 4: Improving Maintenance Therapy for Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.
EP. 5: Role of MRD Assessment in Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.
EP. 6: Approaching Treatment of Relapsed/Refractory Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.
EP. 7: Using IMiD-Based Strategies for Relapsed Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.
EP. 8: CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.
EP. 9: PI-Based Combinations for Relapsed Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center A review of data from key clinical trials, including CANDOR and IKEMA, for relapsed/refractory multiple myeloma.
EP. 10: Treatment of Relapsed/Refractory Myeloma: Novel Agents
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Cristina Gasparetto, MD; Sagar Lonial, MD, FACP; Joseph Mikhael, MD; and Nina Shah, MD, discuss emerging agents available for the treatment of RRMM.
EP. 11: Role of BCMA-Targeted Agents in Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.
EP. 12: Using CAR T Therapy for Relapsed/Refractory Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Nina Shah, MD, leads the discussion on the role of CAR T-cell therapy, including idecabtagene vicleucel, for the management of RRMM.
EP. 13: CARTITUDE-1 and CARTITUDE-2 Trials in Multiple Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.
EP. 14: Investigational Agents for Relapsed/Refractory Myeloma
ByKeith Stewart, MD, ChB, MBA, Mayo Clinic,Sagar Lonial, MD, FACP, Winship Cancer Institute,Cristina Gasparetto, MD, Duke Cancer Institute,Joseph Mikhael, MD, Translational Genomics Research Institute,Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
